Incyte Corporation's shares experienced a 5.6% decline, contrasting with HC Wainwright & Co.'s decision to maintain a Buy rating and raise its price target. The market reaction suggests investor skepticism despite the analyst's positive outlook.
Incyte Shares Fall 5.6% Despite HC Wainwright Buy Rating
INCYPharmaceuticalsAnalyst RatingsStock Movement
